LYCOS RETRIEVER 
Inflammation: Diseases
built 657 days ago
The levels of certain chemicals in your blood are known to increase with increased levels of inflammation. One of these chemical markers for inflammation is a protein called C-reactive protein (CRP). CRP is often measured in conjunction with other blood tests, and normal values are well established. From a clinical standpoint, a CRP level of less than 5 milligrams per liter of blood is considered normal. "Normal" may not be optimal, though. Many medical researchers believe that even slight elevations of CRP are tied to increased risk for heart attack, stroke, and many other diseases.
Source:
In the minds of many, inflammation often is associated with the pain and swelling that occurs after trauma, whether from a sports injury or a wound. However, scientists are beginning to realize that inflammation may actually be the cause behind a surprising number of conditions including Alzheimer’s, cardiovascular disease, hypertension, diabetes/insulin resistance, multiple sclerosis, cancer and depression. Even weight gain is now associated with inflammation. In fact, any condition with a modifier of “itis” at the end of the word (dermatitis, bursitis, colitis, sinusitis, etc.) is linked to inflammation.
Source:
VIA-2291 is a selective and reversible inhibitor of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). Potentially a complement to current standard of care therapies that treat risk factors, such as statins, antiplatelet and blood pressure medications, VIA-2291 is initially targeted to address the secondary prevention market for patients who have already suffered a major adverse cardiovascular event, but eventually could be beneficial to the broader 15.8 million patients in the U.S. who have coronary artery disease. VIA has exclusive worldwide rights to develop and commercialize VIA-2291. Based upon prior trials of VIA-2291 in more than 1,100 patients, VIA believes that VIA-2291 will be safe and well tolerated in doses currently being administered in the ongoing clinical trials.
Source:
"VIA-2291 could provide a novel approach to addressing inflammation in coronary artery disease," said Adeoye Olukotun, MD, chief medical officer of VIA. "This trial is an excellent example of utilizing the benefits of new imaging technology to help accelerate the development of potentially break- through drugs. The use of state-of-the art FDG-PET imaging technology provides an ideal methodology for measuring the effect of VIA-2291 on reducing vascular inflammation in atherosclerosis."
Source:
"Vasogen has previously shown, in a number of different preclinical models, that VP025 has the ability to significantly inhibit neuro-inflammation, which is now implicated as an underlying pathology in ALS," commented Dr. Appel. "These findings suggest that the anti-inflammatory effects of VP025 may be useful in slowing the progression of ALS. There is a desperate need for more effective therapies in ALS and this research could lead to a new approach for the treatment of this devastating disease."
Source:
Abnormalities associated with inflammation comprise a large, unrelated group of disorders which underly a variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. Non-immune diseases with aetiological origins in inflammatory processes are thought to include cancer, atherosclerosis, and ischaemic heart disease.[2]
Source:
MORE ABOUT
Diseases